Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Aloxi Prescribers for CINV: Oncologists (US)

Council Members in this Study Group: 47

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INCDonald Fleming, MD

Division Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

105 recent news post(s)
Taral Patel, MD, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD

Oncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

8 recent news post(s)
Michael Grossbard, MD

Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

87 recent news post(s)
Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD

Medical Director of Hematology
Big Sky Oncology
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Brian Abbott, MD, is the Medical Director of Hematology at Benefis Health System and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including...

5 recent news post(s)
James D'Olimpio, MD

Assistant Professor of Medicine
NEW YORK UNIVERSITY (INC)
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

James D'Olimpio, MD, FACP, is the Director of Palliative Medicine/Cancer Pain and Supportive Oncology at North Shore University Hospital/Monter Cancer Center in Manhasset, New York, and an Assistant Professor of Medicine at New York University School of Medicine. His expertise includes a wide range...

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Triple negative Breast Cancer Strategies

October 14, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

Pay for performance Medicare "reform"

May 4, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Medicare System Overhaul Proposed by Two Senators | www.nytimes.com

Medicare will reward based on outcome Medicare will pay for chronic illness acre based on outcome results Be careful about heading towards cancer care rationing

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Partner
  • Physician - Division Head
  • Medical Director
  • Owner

Related Study Groups

Study Group Name No. Members
Oncologists (US) 2257
Aloxi Prescribers for CINV (US) 36
SRA Prescribers (US) 44
Oncologists who Treat Hematologic Malignancies (US) 858
Hematologists (US) 998
Nexavar Prescribers: Oncologists 73
Physicians who Treat Multiple Myeloma (US) 184